RHAPSODY Trial Results: Recurrent Pericarditis with Rilonacept

Dr. Allan Klein, Director of Cleveland Clinic’s Pericardial Disease Center, provides the results of the RHAPSODY trial, a pivotal Phase 3 trial that evaluated rilonacept, an interleukin 1-α and 1-β inhibitor, compared with placebo among patients with recurrent pericarditis. Study design and findings are provided, as well as implications for future care for patients with pericarditis.